Finley, Alan; Greenberg, Charles (2013-06-01). "Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass". Anesthesia and Analgesia116 (6): 1210–1222. ISSN1526-7598. PMID23408671. doi:10.1213/ANE.0b013e31827e4e62.
Collen D, Schetz J, de Cock F, Holmer E, Verstraete M (1977). "Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis of heparin administration". Eur. J. Clin. Invest.7 (1): 27–35. PMID65284. doi:10.1111/j.1365-2362.1977.tb01566.x.
Conard J, Brosstad F, Lie Larsen M, Samama M, Abildgaard U (1983). "Molar antithrombin concentration in normal human plasma". Haemostasis13 (6): 363–368. PMID6667903. doi:10.1159/000214823.
Jordan RE (1983). "Antithrombin in vertebrate species: Conservation of the heparin-dependent anticoagulant mechanism". Arch. Biochem. Biophys.227 (2): 587–595. PMID6607710. doi:10.1016/0003-9861(83)90488-5.
Olson ST, Björk I (1994). "Regulation of thrombin activity by antithrombin and heparin". Sem. Thromb. Hemost.20 (4): 373–409. PMID7899869. doi:10.1055/s-2007-1001928.
Brennan SO, George PM, Jordan RE (1987). "Physiological variant of antithrombin-III lacks carbohydrate side-chain at Asn 135". FEBS Lett219 (2): 431–436. PMID3609301. doi:10.1016/0014-5793(87)80266-1.
Whisstock JC, Pike RN, et al. (2000). "Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparin". J. Mol. Biol.301 (5): 1287–1305. PMID10966821. doi:10.1006/jmbi.2000.3982.
Schechter I, Berger A (1967). "On the size of the active site in proteases. I. Papain". Biochem. Biophys. Res. Commun.27 (2): 157–162. PMID6035483. doi:10.1016/S0006-291X(67)80055-X.
Persson E, Bak H, Olsen OH (2001). "Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity". J. Biol. Chem.276 (31): 29195–29199. PMID11389142. doi:10.1074/jbc.M102187200.
Ogston D, Murray J, Crawford GP (1976). "Inhibition of the activated Cls subunit of the first component of complement by antithrombin III in the presence of heparin". Thromb. Res.9 (3): 217–222. PMID982345. doi:10.1016/0049-3848(76)90210-3.
Danielsson A, Björk I (1980). "Slow, spontaneous dissociation of the antithrombin-thrombin complex produces a proteolytically modified form of the inhibitor". FEBS Lett119 (2): 241–244. PMID7428936. doi:10.1016/0014-5793(80)80262-6.
Bedsted T, Swanson R, Chuang YJ, Bock PE, Björk I, Olson ST (2003). "Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites". Biochemistry42 (27): 8143–8152. PMID12846563. doi:10.1021/bi034363y.
Langdown J, Johnson DJ, Baglin TP, Huntington JA (2004). "Allosteric activation of antithrombin critically depends upon hinge region extension". J. Biol. Chem.279 (45): 47288–47297. PMID15326167. doi:10.1074/jbc.M408961200.
Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJ, Grootenhuis PD, Hol WG (1994). "The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions". Nature Structural & Molecular Biology1 (1): 48–54. PMID7656006. doi:10.1038/nsb0194-48.
Carrell RW, Stein PE, Fermi G, Wardell MR (1994). "Biological implications of a 3 A structure of dimeric antithrombin". Structure2 (4): 257–270. PMID8087553. doi:10.1016/S0969-2126(00)00028-9.
Petitou M, Hérault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM (1999). "Synthesis of Thrombin inhibiting Heparin mimetics without side effects". Nature398 (6726): 417–422. PMID10201371. doi:10.1038/18877.
Li W, Johnson DJ, Esmon CT, Huntington JA (2004). "Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin". Nature Structural & Molecular Biology11 (9): 857–862. PMID15311269. doi:10.1038/nsmb811.
McCoy AJ, Pei XY, Skinner R, Abrahams JP, Carrell RW (2003). "Structure of beta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity". J. Mol. Biol.326 (3): 823–833. PMID12581643. doi:10.1016/S0022-2836(02)01382-7.
Turk B, Brieditis I, Bock SC, Olson ST, Björk I (1997). "The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change". Biochemistry36 (22): 6682–6691. PMID9184148. doi:10.1021/bi9702492.
Olds RJ, Lane DA, Beresford CH, Abildgaard U, Hughes PM, Thein SL (1993). "A recurrent deletion in the antithrombin gene, AT106-108(-6 bp), identified by DNA heteroduplex detection". Genomics16 (1): 298–299. PMID8486379. doi:10.1006/geno.1993.1184.
Olds RJ, Lane DA, Ireland H, Finazzi G, Barbui T, Abildgaard U, Girolami A, Thein SL (1991). "A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop)". Thromb. Res.64 (5): 621–625. PMID1808766. doi:10.1016/S0049-3848(05)80011-8.
Allingstrup, Mikkel; Wetterslev, Jørn; Ravn, Frederikke B.; Møller, Ann Merete; Afshari, Arash (9 February 2016). "Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis". Intensive Care Medicine42 (4): 505–520. PMID26862016. doi:10.1007/s00134-016-4225-7.
Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ (1992). "Structural basis of latency in plasminogen activator inhibitor-1". Nature355 (6357): 270–273. PMID1731226. doi:10.1038/355270a0.
Wardell MR, Chang WS, Bruce D, Skinner R, Lesk AM, Carrell RW (1997). "Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1". Biochemistry36 (42): 13133–13142. PMID9335576. doi:10.1021/bi970664u.
Larsson H, Akerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, Björk I (2001). "A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity". J. Biol. Chem.276 (15): 11996–12002. PMID11278631. doi:10.1074/jbc.M010170200.
O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999). "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin". Science285 (5435): 1926–1928. PMID10489375. doi:10.1126/science.285.5435.1926.
Yin ET, Wessler S, Stoll PJ (1971). "Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor". J. Biol. Chem.246 (11): 3712–3719. PMID4102937.
Collen D, Schetz J, de Cock F, Holmer E, Verstraete M (1977). "Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis of heparin administration". Eur. J. Clin. Invest.7 (1): 27–35. PMID65284. doi:10.1111/j.1365-2362.1977.tb01566.x.
Conard J, Brosstad F, Lie Larsen M, Samama M, Abildgaard U (1983). "Molar antithrombin concentration in normal human plasma". Haemostasis13 (6): 363–368. PMID6667903. doi:10.1159/000214823.
Jordan RE (1983). "Antithrombin in vertebrate species: Conservation of the heparin-dependent anticoagulant mechanism". Arch. Biochem. Biophys.227 (2): 587–595. PMID6607710. doi:10.1016/0003-9861(83)90488-5.
Olson ST, Björk I (1994). "Regulation of thrombin activity by antithrombin and heparin". Sem. Thromb. Hemost.20 (4): 373–409. PMID7899869. doi:10.1055/s-2007-1001928.
Brennan SO, George PM, Jordan RE (1987). "Physiological variant of antithrombin-III lacks carbohydrate side-chain at Asn 135". FEBS Lett219 (2): 431–436. PMID3609301. doi:10.1016/0014-5793(87)80266-1.
Zettlmeissl G, Conradt HS, Nimtz M, Karges HE (1989). "Characterization of recombinant human antithrombin III synthesized in Chinese hamster ovary cells". J. Biol. Chem.264 (35): 21153–21159. PMID2592368.
Gillespie LS, Hillesland KK, Knauer DJ (1991). "Expression of biologically active human antithrombin III by recombinant baculovirus in Spodoptera frugiperda cells". J. Biol. Chem.266 (6): 3995–4001. PMID1995647.
Whisstock JC, Pike RN, et al. (2000). "Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparin". J. Mol. Biol.301 (5): 1287–1305. PMID10966821. doi:10.1006/jmbi.2000.3982.
Schechter I, Berger A (1967). "On the size of the active site in proteases. I. Papain". Biochem. Biophys. Res. Commun.27 (2): 157–162. PMID6035483. doi:10.1016/S0006-291X(67)80055-X.
Persson E, Bak H, Olsen OH (2001). "Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity". J. Biol. Chem.276 (31): 29195–29199. PMID11389142. doi:10.1074/jbc.M102187200.
Ogston D, Murray J, Crawford GP (1976). "Inhibition of the activated Cls subunit of the first component of complement by antithrombin III in the presence of heparin". Thromb. Res.9 (3): 217–222. PMID982345. doi:10.1016/0049-3848(76)90210-3.
Danielsson A, Björk I (1980). "Slow, spontaneous dissociation of the antithrombin-thrombin complex produces a proteolytically modified form of the inhibitor". FEBS Lett119 (2): 241–244. PMID7428936. doi:10.1016/0014-5793(80)80262-6.
Bedsted T, Swanson R, Chuang YJ, Bock PE, Björk I, Olson ST (2003). "Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites". Biochemistry42 (27): 8143–8152. PMID12846563. doi:10.1021/bi034363y.
Jordan RE, Oosta GM, Gardner WT, Rosenberg RD (1980). "The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin". J. Biol. Chem.255 (21): 10081–10090. PMID6448846.
Griffith MJ (1982). "Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin". J. Biol. Chem.257 (13): 7360–7365. PMID7085630.
Olson ST, Björk I (1991). "Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects". J. Biol. Chem.266 (10): 6353–6354. PMID2007588.
Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J (1992). "Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement". J. Biol. Chem.267 (18): 12528–12538. PMID1618758.
Langdown J, Johnson DJ, Baglin TP, Huntington JA (2004). "Allosteric activation of antithrombin critically depends upon hinge region extension". J. Biol. Chem.279 (45): 47288–47297. PMID15326167. doi:10.1074/jbc.M408961200.
Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJ, Grootenhuis PD, Hol WG (1994). "The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions". Nature Structural & Molecular Biology1 (1): 48–54. PMID7656006. doi:10.1038/nsb0194-48.
Carrell RW, Stein PE, Fermi G, Wardell MR (1994). "Biological implications of a 3 A structure of dimeric antithrombin". Structure2 (4): 257–270. PMID8087553. doi:10.1016/S0969-2126(00)00028-9.
Petitou M, Hérault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM (1999). "Synthesis of Thrombin inhibiting Heparin mimetics without side effects". Nature398 (6726): 417–422. PMID10201371. doi:10.1038/18877.
Li W, Johnson DJ, Esmon CT, Huntington JA (2004). "Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin". Nature Structural & Molecular Biology11 (9): 857–862. PMID15311269. doi:10.1038/nsmb811.
McCoy AJ, Pei XY, Skinner R, Abrahams JP, Carrell RW (2003). "Structure of beta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity". J. Mol. Biol.326 (3): 823–833. PMID12581643. doi:10.1016/S0022-2836(02)01382-7.
Turk B, Brieditis I, Bock SC, Olson ST, Björk I (1997). "The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change". Biochemistry36 (22): 6682–6691. PMID9184148. doi:10.1021/bi9702492.
Sas G, Petö I, Bánhegyi D, Blaskó G, Domján G (1980). "Heterogeneity of the "classical" antithrombin III deficiency". Thromb. Haemost.43 (2): 133–136. PMID7455972.
Sas G (1984). "Hereditary antithrombin III deficiency: biochemical aspects". Haematologia17 (1): 81–86. PMID6724355.
Lane DA, Olds RJ, Boisclair M, Chowdhury V, Thein SL, Cooper DN, Blajchman M, Perry D, Emmerich J, Aiach M (1993). "Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis". Thromb. Haemost.70 (2): 361–369. PMID8236149.
Olds RJ, Lane DA, Beresford CH, Abildgaard U, Hughes PM, Thein SL (1993). "A recurrent deletion in the antithrombin gene, AT106-108(-6 bp), identified by DNA heteroduplex detection". Genomics16 (1): 298–299. PMID8486379. doi:10.1006/geno.1993.1184.
Olds RJ, Lane DA, Ireland H, Finazzi G, Barbui T, Abildgaard U, Girolami A, Thein SL (1991). "A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop)". Thromb. Res.64 (5): 621–625. PMID1808766. doi:10.1016/S0049-3848(05)80011-8.
Blajchman MA, Austin RC, Fernandez-Rachubinski F, Sheffield WP (1992). "Molecular basis of inherited human antithrombin deficiency". Blood80 (9): 2159–2171. PMID1421387.
Allingstrup, Mikkel; Wetterslev, Jørn; Ravn, Frederikke B.; Møller, Ann Merete; Afshari, Arash (9 February 2016). "Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis". Intensive Care Medicine42 (4): 505–520. PMID26862016. doi:10.1007/s00134-016-4225-7.
Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ (1992). "Structural basis of latency in plasminogen activator inhibitor-1". Nature355 (6357): 270–273. PMID1731226. doi:10.1038/355270a0.
Wardell MR, Chang WS, Bruce D, Skinner R, Lesk AM, Carrell RW (1997). "Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1". Biochemistry36 (42): 13133–13142. PMID9335576. doi:10.1021/bi970664u.
Carrell RW, Huntington JA, Mushunje A, Zhou A (2001). "The conformational basis of thrombosis". Thromb. Haemost.86 (1): 14–22. PMID11487000.
Zhou A, Huntington JA, Carrell RW (1999). "Formation of the antithrombin heterodimer in vivo and the onset of thrombosis". Blood94 (10): 3388–3396. PMID10552948.
Larsson H, Akerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, Björk I (2001). "A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity". J. Biol. Chem.276 (15): 11996–12002. PMID11278631. doi:10.1074/jbc.M010170200.
O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999). "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin". Science285 (5435): 1926–1928. PMID10489375. doi:10.1126/science.285.5435.1926.
A.M.Venneröd, K.Laakea, A. K. Solberga, S. Strömlanda. Inactivation and binding of human plasma kallikrein by antithrombin III and heparin. Thrombosis Research. Volume 9, Issue 5, November 1976, Pages 457-466. [1][2] doi.org/10.1016/0049-3848(76)90201-2
A.M.Venneröd, K.Laakea, A. K. Solberga, S. Strömlanda. Inactivation and binding of human plasma kallikrein by antithrombin III and heparin. Thrombosis Research. Volume 9, Issue 5, November 1976, Pages 457-466. [1][2] doi.org/10.1016/0049-3848(76)90201-2
M.W.C. Hatton, E. Regoeczi. The inactivation of thrombin and plasmin by antithrombin III in the presence of Sepharose-heparin. Thrombosis research. May 1977. Volume 10, Issue 5, Pages 645–660. [3] /doi.org/10.1016/0049-3848(77)90047-0
